- Details
- Description
-
Packaging Size1Bottle/Box
-
Strength10mg/1mL
-
CompositonSerplulimab
-
TreatmentSmall Cell Lung Cancer (SCLC)
-
FormInjection
-
BrandZerpidio状（汉斯状）
-
Quantity Unit100mg(10ml)/Bottle
-
ManufacturerHenlius Biopharmaceutical Company
Zerpidio (Serplulimab) sold under the brand name 汉斯状 in china.
Serplulimab, a recombinant humanised anti-PD-1 monoclonal antibody (mAb) injection, is the first innovative monoclonal antibody developed by Henlius.
It has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) and the European Commission (EC) for the treatment of Small Cell Lung Cancer (SCLC). Its marketing application for the first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) is under review by the EMA.
Serplulimab was launched in China under the trade name HANSIZHUANG（汉斯状） in March 2022 and has been approved by the NMPA for the treatment of MSI-H solid tumours, squamous non-small cell lung cancer (sqNSCLC), ES-SCLC, and esophageal squamous cell carcinoma (ESCC).
Oct. 27, 2023 - Intas Pharmaceuticals Limited ("Intas") has entered into an exclusive license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) for the development and commercialisation of serplulimab for Europe and India markets.
Jan. 25, 2024 Zerpidio® start set sail for Indonesia. Zerpidio® in Indonesia for the treatment of extensive stage small cell lung cancer (ES-SCLC).
